Leqembi Q3 Sales Total 32.2 Billion Yen as BioArctic Royalty Rises 74%
BioArctic AB said on October 28, 2026 that its partner Eisai published preliminary global revenue for the Alzheimer's disease treatment Leqembi (lecanemab) totaling 32.2 billion Japanese yen in the third quarter of 2026. The figure, released in conjunction with partner Biogen's third-quarter report, results in a royalty to BioArctic of 203.8 million Swedish kronor, an increase of approximately 74 percent compared with the royalty BioArctic recorded for the third quarter of 2025, according to…